Impact of underlying diseases on the clinical characteristics and outcome of primary pyomyositis
- PMID: 18787734
Impact of underlying diseases on the clinical characteristics and outcome of primary pyomyositis
Abstract
Background and purpose: Primary pyomyositis is increasingly recognized in non-tropical areas, its incidence seeming to mirror the increase in immunocompromised populations. In this study, we sought to analyze the differences in clinical characteristics, causative organisms, treatment and outcome between pyomyositis patients with and without underlying diseases.
Methods: Thirty five patients with a diagnosis of primary pyomyositis seen in our hospital between July 1989 and July 2006 were enrolled. Descriptive information concerning age, gender, clinical features, underlying comorbid diseases, results of blood tests, blood culture, muscle or pus culture, disease severity and clinical stages at the time of diagnosis, therapy, and outcome were collected by review of medical charts.
Results: Of the 23 cases with underlying diseases, the mean age was 47.8 years (range, 24 to 79 years). Of the 12 patients without underlying diseases, the mean age was 26.2 years (range, 2 to 72 years). The lower extremities was the most common site of involvement. Staphylococcus aureus was the most frequent causative organism. Gram-negative organisms were isolated in 30.4% of patients with underlying diseases and in none of the patients without underlying diseases (p=0.07). Positive blood culture was significantly more common in patients with underlying diseases than in patients without underlying diseases (52.2% vs 8.3%, p=0.013). The mortality rate was higher in patients with underlying diseases than in patients without underlying diseases (39.1% vs 0.0%, p=0.015). White blood cell count (p=0.017), Acute Physiology and Chronic Health Evaluation (APACHE) II score (p<0.001), recurrence (p=0.004), and presence of underlying diseases (p=0.015) were significant prognostic factors for mortality by univariate analysis. APACHE II score (odds ratio, 1.57; 95% confidence interval, 1.13 to 2.20; p=0.008) was found to be a significant independent risk factor for mortality in multivariate logistic regression analysis. For prediction of mortality, the best cut-off point in APACHE II score was 16 (sensitivity, 77.8%; specificity, 92.3%; accuracy, 88.6%).
Conclusions: Patients with primary pyomyositis should be treated with appropriate broad-spectrum antibiotics and be monitored closely for complications. This study found that patients who suffered from primary pyomyositis with underlying diseases had a higher rate of Gram-negative bacterial infections, bacteremia and mortality. The APACHE II score at diagnosis was found to be an independent prognostic factor for mortality.
Similar articles
-
Impact of antibiotic-resistant Gram-negative bacilli infections on outcome in hospitalized patients.Crit Care Med. 2003 Apr;31(4):1035-41. doi: 10.1097/01.CCM.0000060015.77443.31. Crit Care Med. 2003. PMID: 12682469
-
Outcome analysis of patients requiring mechanical ventilation with severe community-acquired pneumonia and identified bacterial pathogens.Chang Gung Med J. 2005 Apr;28(4):229-36. Chang Gung Med J. 2005. PMID: 16013342
-
Risk factors for relapse of ventilator-associated pneumonia in trauma patients.J Trauma. 2009 Jul;67(1):91-5; discussion 95-6. doi: 10.1097/TA.0b013e3181a8b2b2. J Trauma. 2009. PMID: 19590315
-
Enterococcal meningitis: a clinical study of 39 cases and review of the literature.Medicine (Baltimore). 2003 Sep;82(5):346-64. doi: 10.1097/01.md.0000090402.56130.82. Medicine (Baltimore). 2003. PMID: 14530784 Review.
-
Bloodstream infections in cancer patients with febrile neutropenia.Int J Antimicrob Agents. 2008 Nov;32 Suppl 1:S30-3. doi: 10.1016/j.ijantimicag.2008.06.017. Epub 2008 Sep 7. Int J Antimicrob Agents. 2008. PMID: 18778919 Review.
Cited by
-
Enterobacter cloacae pyomyositis complicating chronic granulomatous disease and review of gram-negative bacilli pyomyositis.Eur J Clin Microbiol Infect Dis. 2013 Jun;32(6):729-34. doi: 10.1007/s10096-013-1815-y. Epub 2013 Feb 1. Eur J Clin Microbiol Infect Dis. 2013. PMID: 23370968 Review.
-
Pyomyositis associated with chemotherapy for endometrial cancer: a case report.World J Surg Oncol. 2013 Feb 25;11:45. doi: 10.1186/1477-7819-11-45. World J Surg Oncol. 2013. PMID: 23442230 Free PMC article.
-
Pyomyositis in a Patient Undergoing Chemotherapy for Gastric Cancer: A Case Report and Literature Review.Case Rep Oncol. 2021 Aug 16;14(2):1220-1227. doi: 10.1159/000518242. eCollection 2021 May-Aug. Case Rep Oncol. 2021. PMID: 34703439 Free PMC article.
-
Pelvic Pyomyositis in Childhood: Clinical and Radiological Findings in a Tertiary Pediatric Center.Children (Basel). 2022 May 9;9(5):685. doi: 10.3390/children9050685. Children (Basel). 2022. PMID: 35626862 Free PMC article.
-
Uncommon primary Group A streptococcal erector spinae pyomyositis diagnosed as muscle strain in a fit young male.SAGE Open Med Case Rep. 2019 Apr 1;7:2050313X19840243. doi: 10.1177/2050313X19840243. eCollection 2019. SAGE Open Med Case Rep. 2019. PMID: 30967957 Free PMC article.